⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 21, 2019JAMAOpen Access

Trends in Levels of Lipids and Apolipoprotein B in US Youths Aged 6 to 19 Years, 1999-2016

Amanda M. Perak Hongyan Ning Brian K. Kit Sarah D. de Ferranti Linda Van Horn John T. Wilkins Donald M. Lloyd‐Jones

View Full Paper

Ask AI

Bookmark

Share

Abstract

Between 1999 and 2016, favorable trends were observed in levels of lipids and apolipoprotein B in US youths aged 6 to 19 years.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Perak et al. (2019) studied this question.

synapsesocial.com/papers/6959a08a3b2fbdad0874b6c6 https://doi.org/10.1001/jama.2019.4984

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reductionother · 2010 · 4,749 citations
2Cardiovascular Health Promotion in Children: Challenges and Opportunities for 2020 and Beyond: A Scientific Statement From the American Heart Associationreview · 2016 · 300 citations
3Association between Multiple Cardiovascular Risk Factors and Atherosclerosis in Children and Young AdultsOriginal Research · 1998 · 4,033 citations
4Effects of Serum Lipoproteins and Smoking on Atherosclerosis in Young Men and Womencross-sectional · 1997 · 437 citations
5Associations of Coronary Heart Disease Risk Factors With the Intermediate Lesion of Atherosclerosis in Youthcross-sectional · 2000 · 421 citations

More related papers

Usefulness of Childhood Non–High Density Lipoprotein Cholesterol Levels Versus Other Lipoprotein Measures in Predicting Adult Subclinical Atherosclerosis: The Bogalusa Heart Study2008
Trends in Serum Lipids Among US Youths Aged 6 to 19 Years, 1988-20102012
Prevalence of and Trends in Dyslipidemia and Blood Pressure Among US Children and Adolescents, 1999-20122015

More from JAMA

Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and ErythropoiesisSat,
Increased Hemoglobin With Sodium-Glucose Transporter 2 Inhibitors—A Consistent Extra Benefit?Sat,